Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd-Rüdiger Balda
Michael Hertl

Showing results (131-140 of 180) with videos related to

Pageof 18
Sort By:
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|May 22, 2020
[European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology]Eva Hadaschik, Rüdiger Eming, Lars E French, et al.
Journal of Clinical Medicine|July 13, 2024
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBestBrigitte Stephan, Stephan Jeff Rustenbach, Nesrine Ben-Anaya, et al.
The Journal of Investigative Dermatology|June 24, 2011
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter studyGiovanni Di Zenzo, Sybille Thoma-Uszynski, Valentina Calabresi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 19, 2017
Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der DermatologieAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 31, 2016
European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatologyAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 17, 2024
Pathogenic relevance of antibodies against desmoglein 3 in patients with oral lichen planusDario Didona, Morna F Schmidt, Katharina Meier, et al.
Frontiers in Immunology|June 6, 2022
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus FoliaceusMaud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, et al.
The British Journal of Dermatology|May 12, 2024
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE studyThierry Passeron, Maximilian Reinhardt, Benjamin Ehst, et al.
BMC Immunology|April 5, 2012
Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseasesEmilia Licarete, Susanne Ganz, Martin J Recknagel, et al.
The Journal of Investigative Dermatology|September 11, 2022
IgG against the Membrane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pemphigus VulgarisChristoph Hudemann, Yvonne Exner, Robert Pollmann, et al.
Pageof 18

Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|May 22, 2020
[European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology]Eva Hadaschik, Rüdiger Eming, Lars E French, et al.
Journal of Clinical Medicine|July 13, 2024
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBestBrigitte Stephan, Stephan Jeff Rustenbach, Nesrine Ben-Anaya, et al.
The Journal of Investigative Dermatology|June 24, 2011
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter studyGiovanni Di Zenzo, Sybille Thoma-Uszynski, Valentina Calabresi, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 19, 2017
Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der DermatologieAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 31, 2016
European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatologyAlexander Enk, Eva Hadaschik, Rüdiger Eming, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 17, 2024
Pathogenic relevance of antibodies against desmoglein 3 in patients with oral lichen planusDario Didona, Morna F Schmidt, Katharina Meier, et al.
Frontiers in Immunology|June 6, 2022
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus FoliaceusMaud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, et al.
The British Journal of Dermatology|May 12, 2024
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE studyThierry Passeron, Maximilian Reinhardt, Benjamin Ehst, et al.
BMC Immunology|April 5, 2012
Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseasesEmilia Licarete, Susanne Ganz, Martin J Recknagel, et al.
The Journal of Investigative Dermatology|September 11, 2022
IgG against the Membrane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pemphigus VulgarisChristoph Hudemann, Yvonne Exner, Robert Pollmann, et al.
Pageof 18